Company profile: Veru
1.1 - Company Overview
Company description
- Provider of novel medicines and healthcare products, including enobosarm to prevent muscle loss in patients using GLP-1 drugs and to treat metastatic breast cancer; sabizabulin for hospitalized patients with viral-induced ARDS; and the FDA-approved FC2 Female Condom for prevention of pregnancy and sexually transmitted infections, available by prescription.
Products and services
- Enobosarm: GLP-1–adjunct therapeutic-grade medicine developed to prevent muscle loss during weight loss therapy and to treat metastatic breast cancer
- FC2 Female Condom: FDA-approved female condom engineered to prevent pregnancy and sexually transmitted infections, and is available by prescription
- Sabizabulin: Hospital-grade therapy developed as a treatment for hospitalized patients with viral-induced ARDS in inpatient settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Veru
Pin Therapeutics
HQ: South Korea
Website
- Description: Provider of advanced protein degradation therapeutics, utilizing biological pathways of proteostasis to develop therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pin Therapeutics company profile →
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
Bristol Myers Squibb
HQ: United States
Website
- Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bristol Myers Squibb company profile →
Bliss Biopharma
HQ: China
Website
- Description: Provider of tumor-targeting and immunotherapy therapeutics, focused on antibody-drug conjugates (ADCs). Offers BB-1701, an anti-HER2 ADC in international multi-center trials for HER2-positive solid tumors, and a diverse ADC pipeline in preclinical and clinical stages. Operates in-house, GMP-compliant antibody and ADC manufacturing to support clinical development and early commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bliss Biopharma company profile →
Pernix Therapeutics
HQ: United States
Website
- Description: Provider of branded and generic pharmaceutical products for the pediatric market, specializing in the sales, marketing, and development of products designed to improve children's health and well-being, including offerings in allergy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pernix Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Veru
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Veru
2.2 - Growth funds investing in similar companies to Veru
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Veru
4.2 - Public trading comparable groups for Veru
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →